{"entity":{"id":"nct06404736","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","aka":["QUEEN-Dream"],"tldr":"A phase 2 trial of nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer is a phase 2, interventional study registered as NCT06404736 by Fudan University, with a registry enrolment figure of 73 participants, started 2024-05-07 and due to reach its primary completion in 2025-11-07. Interventions recorded: Bispecific antibody (bsAb) targeting PD-1 and CLTA-4; Albumin-bound paclitaxel; Carboplatin. Conditions listed: Early Breast Cancer; Neoadjuvant Therapy; TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"According to the definition of the latest ASCO/CAP guidelines, histopathologically confirmed TNBC breast cancer, histological grade II, TNM stage T1cN1-cN2 or T2-T4, cN0-cN2;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06404736","url":"https://clinicaltrials.gov/study/NCT06404736"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["nab-paclitaxel","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06404736","phase":"2","setting":"A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-Stage Breast Cancer (QUEEN-Dream)","sponsor":"Fudan University","participation":[{"nct":"NCT06404736","source":"https://clinicaltrials.gov/study/NCT06404736","fetchedAt":"2026-10-07T16:54:38.047Z","studySha256":"72fe84665759e2adf4a6788d74660964883aa9a8b4c3ef6cdb759d23dd793991","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-05-08","leadSponsor":"Fudan University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":73,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-05-07","startedType":"estimated","enrolled":73,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06404736/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}